Marie-France Tschudin

President of Novartis Pharmaceuticals at Novartis AG

Marie-France Tschudin

Marie-France Tschudin

President of Novartis Pharmaceuticals at Novartis AG

Overview
Career Highlights

Advanced Accelerator Applications SA

RelSci Relationships

286

Number of Boards

4

Birthday

1971

Age

49

Relationships
RelSci Relationships are individuals Marie-France Tschudin likely has professional access to. A relationship does not necessarily indicate a personal connection.

General Manager Region Europe Oncology at Novartis Venture Fund

Relationship likelihood: Strong

Chief Financial Officer at Advanced Accelerator Applications SA

Relationship likelihood: Strong

Chief Operations Officer at Advanced Accelerator Applications SA

Relationship likelihood: Strong

Director at Abeona Therapeutics LLC

Relationship likelihood: Strong

Partner at Tre A SRL

Relationship likelihood: Strong

Head of Research & Development at Advanced Accelerator Applications SA

Relationship likelihood: Strong

Head of Quality Assurance at Advanced Accelerator Applications SA

Relationship likelihood: Strong

Chairman & President at Advanced Accelerator Applications SA

Relationship likelihood: Strong

Head-Technical Operations at Advanced Accelerator Applications SA

Relationship likelihood: Strong

Former Chief Operating Officer at Advanced Accelerator Applications SA

Relationship likelihood: Strong

Paths to Marie-France Tschudin
Potential Connections via
Relationship Science
You
Marie-France Tschudin
President of Novartis Pharmaceuticals at Novartis AG
Education

Georgetown University is a private research university in Washington, D.C. Founded in 1789, it is the oldest Jesuit and Catholic university in the United States. Georgetown's main campus, located in Washington's Georgetown neighborhood, is noted for Healy Hall, a National Historic Landmark in the Romanesque revival style. Georgetown operates a law center on Capitol Hill and auxiliary campuses in Italy, Turkey, and Qatar.

IMD business school is located in Lausanne, Switzerland. It consistently ranks at the top compared to other business schools worldwide. In 2012 and 2013, it was ranked first in open programs worldwide by the Financial Times. Its MBA program is ranked among the top tier programs in the world.

Career History
President
? - 2019

Advanced Accelerator Applications SA is a radiopharmaceutical company, which develops, produces and commercializes molecular nuclear medicine products. The firm offers research and development in medicinal and pharmaceutical therapeutic products mainly focusing in cardiology and neurology. It manufactures both diagnostic and therapeutic MNM products for commercialization. The company was founded by Stefano Buono in 2002 and is headquartered in Saint Genis Pouilly, France.

President of Novartis Pharmaceuticals
2019 - Current

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Boards & Committees
Independent Director
2020 - Current

AXA SA operates as a holding company, which engages in the provision of insurance and asset management services. It operates through the following segments: France, Europe, Asia, AXA XL, the United States, International and Transversal & Central Holdings. The France segment consists of Life & Savings and Property & Casualty activities, AXA Banque France and France holdings. The Europe segment consists of Life & Savings and Property & Casualty activities in Switzerland, Germany, Belgium, United Kingdom & Ireland, Spain and Italy. The Asian segment consists of Life & Savings activities in Japan, Hong Kong and Asia High Potentials as well as Property & Casualty activities in Hong Kong and Asia High Potentials. The AXA XL segment consists of Property & Casualty activities at XL Group, as well as AXA Corporate Solutions Assurance and AXA Art. The United States segment includes Life & Savings activities in United States, as well as Asset Management services offered by AB. The International segment consists of Life & Savings and Property & Casualty activities in 14 countries within Europe, Middle East, and Africa & Latin America as well as in Singapore, in Malaysia and in India. The Transversal & Central Holdings segment includes transversal entities namely AXA Investment Managers, AXA Assistance, AXA Liabilities Managers, AXA Global Re, AXA Life Europe, as well as AXA SA and other Central Holdings. The company was founded in 1985 and is headquartered in Paris, France.

Member, Executive Committee
Current

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Member, Executive Committee
Prior

Advanced Accelerator Applications SA is a radiopharmaceutical company, which develops, produces and commercializes molecular nuclear medicine products. The firm offers research and development in medicinal and pharmaceutical therapeutic products mainly focusing in cardiology and neurology. It manufactures both diagnostic and therapeutic MNM products for commercialization. The company was founded by Stefano Buono in 2002 and is headquartered in Saint Genis Pouilly, France.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Marie-France Tschudin. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Marie-France Tschudin's profile does not indicate a business or promotional relationship of any kind between RelSci and Marie-France Tschudin.